PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

Description: PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech's Meningitec, Novartis' Menjugate kit, and Baxter's NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013).

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain

Contents:

1
1 List of Tables
1.1 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Meningococcal Immunization Policy
4.2 Spain
4.2.1 Meningococcal Immunization Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Menveo
5.3.2 Nimenrix
5.3.3 Meningitec
5.3.4 Menjugate
5.3.5 NeisVac-C
5.3.6 Menomune
5.3.7 Bexsero
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Unmet Need: Protection Against Serogroup B Disease
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine
6.2.3 Unmet Need: More Cost-Effective Vaccines
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents
6.2.5 Unmet Need: Immunogenic Infant Vaccines
6.2.6 Unmet Need: Improved Vaccination Coverage Rates
6.2.7 Unmet Need: Increased Patient Awareness and Education
6.3 Unmet Needs Gap Analysis
6.4 Opportunities
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets
7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development
7.2.1 MnB rLP2086
7.3 Promising Vaccines in Early Clinical Development
8 Market Outlook
8.1 Spain
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion
9.4.3 Vaccines Included
9.4.4 Key Launch Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.4.7 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Authors
9.6.2 Reviewers
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Meningococcal Immunization Recommendation Agencies by Country
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
Table 4: Leading Vaccines for Meningococcal Disease, 2012
Table 5: Product Profile – Menveo
Table 6: Menveo SWOT Analysis, 2012
Table 7: Product Profile – Nimenrix
Table 8: Nimenrix SWOT Analysis, 2012
Table 9: Product Profile – Meningitec
Table 10: Meningitec SWOT Analysis, 2012
Table 11: Product Profile – Menjugate
Table 12: Menjugate SWOT Analysis, 2012
Table 13: Product Profile – NeisVac-C
Table 14: NeisVac-C SWOT Analysis, 2012
Table 15: Product Profile – Menomune
Table 16: Menomune SWOT Analysis, 2012
Table 17: Product Profile – Bexsero
Table 18: Bexsero SWOT Analysis, 2012
Table 19: Overall Unmet Needs – Current Level of Attainment
Table 20: Clinical Unmet Needs – Gap Analysis, 2012
Table 21: Meningococcal Vaccines – Phase Pipeline, 2012
Table 22: Comparison of Vaccines in Development for Meningococcal Disease, 2012
Table 23: Product Profile – MnB rLP2086
Table 24: MnB rLP2086 SWOT Analysis, 2012
Table 25: Sales Forecasts ($m) for Meningococcal Vaccines in Spain, 2012–2022
Table 26: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2012–2022
Table 27: Spain Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022
Table 28: Key Launch Dates
Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012–2022
Figure 3: Sales for Meningococcal Vaccines in Spain by Vaccine Class, 2012–2022

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2588296/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2588296/
Office Code: SC616YIP

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Site License</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 14985</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World